相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Professor Tricia Naicker, one of South Africa's youngest full professors in Synthetic Chemistry at UKZN, won the Distinguished Young Woman Researcher award at the 23rd SAWiSA ceremony in Johannesburg. - Her research develops novel chemical compounds to combat antimicrobial resistance, including metallo-β-lactamase inhibitors capable of restoring the effectiveness of existing antibiotics. - Some of her compounds are now entering Phase 1 clinical trials, marking a significant step toward addressing a major global health challenge. - With an NRF C1 rating, she has authored more than 130 peer-reviewed publications and supervised over 35 postgraduate students, strengthening Africa's drug discovery capacity.
- A groundbreaking clinical trial in South Africa has achieved a potential HIV cure in one young woman using a novel "kick and kill" therapeutic approach, marking the first successful HIV cure trial conducted in Africa. - The FRESH trial enrolled 20 women and used vesatolimod to flush HIV from cellular reservoirs followed by broadly neutralizing antibodies, resulting in four participants achieving remission with 20% showing long-term viral control. - This milestone represents a critical advancement for HIV treatment in Africa, where 67% of the world's 40.8 million HIV patients live, addressing the urgent need for cure strategies tailored to African populations and viral strains.
• Gilead Sciences has initiated the first known HIV cure trial in South Africa, specifically targeting women who are significantly underrepresented in HIV clinical research despite bearing a disproportionate disease burden. • The trial enrolled 20 young women from the FRESH (Females Rising through Education, Support and Health) cohort in KwaZulu-Natal, where women face a 66% chance of HIV infection by their mid-30s. • Participants were recruited from a program that provides early HIV detection and immediate treatment, creating a unique population with small viral reservoirs that may be more responsive to immunotherapy-based cure approaches.
- A groundbreaking Phase IIa clinical trial in South Africa has demonstrated that a combination of broadly neutralizing antibodies and immune stimulants may enable some HIV patients to control the virus without daily antiretroviral therapy. - Led by Professor Thumbi Ndung'u at the Africa Health Research Institute, the study enrolled 20 South African women who received vesatolimod and two potent antibodies (VRC07-523LS and CAP256V2LS), with one participant maintaining viral control for 2.5 years after stopping treatment. - The trial represents the first HIV remission study conducted on African soil, addressing a critical need in KwaZulu-Natal where HIV prevalence reaches nearly 60% among women aged 25-44, and demonstrating that complex HIV cure research can succeed in resource-limited settings.
